CA
CCCC icon

CV Advisors’s C4 Therapeutics CCCC Stock Holding History

CV Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
+65,000
New +$222K 0.06% 106

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

CV Advisors's CCCC Position: Q2 2026 in Review

CV Advisors opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 65,000 shares worth $304K. The stake represents 0.06% of the portfolio and ranks #106 among its holdings.

8 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • CV Advisors held 65,000 shares of C4 Therapeutics worth $304K as of Q2 2026.
  • C4 Therapeutics was a new CV Advisors position in Q2 2026.
  • C4 Therapeutics made up 0.06% of CV Advisors's portfolio in Q2 2026, its #106 holding.
  • 8 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on CV Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.